GSK-5733584
- Generic Name
- GSK-5733584
A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Tumours, Gynecological
- Interventions
- Drug: Anticancer therapy 1Drug: Anticancer therapy 2Drug: Anticancer therapy 3Drug: Anticancer therapy 4
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 360
- Registration Number
- NCT06796907
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3
Not yet recruiting
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 468
- Registration Number
- NCT06855069
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT06431594
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 1048
- Registration Number
- NCT06336707
- Locations
- 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Shanghai, Shanghai, China
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Phase 2
Recruiting
- Conditions
- Endometrial CancerOvarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 460
- Registration Number
- NCT06014190
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Hunan Cancer Hosipital, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath